Can I read Left Ventricular Dysfunction Among Patients With Embolic Stroke of Undetermined Source and the Effect of Rivaroxaban vs Aspirin: A Subgroup Analysis of the NAVIGATE ESUS Randomized Clinical Trial on EtoBox?
Left Ventricular Dysfunction Among Patients With Embolic Stroke of Undetermined Source and the Effect of Rivaroxaban vs Aspirin: A Subgroup Analysis of the NAVIGATE ESUS Randomized Clinical Trial by Alexander E. Merkler; Lesly A. Pearce; Scott E. Kasner; Ashkan Shoamanesh; Lee A. Birnbaum; Hooman Kamel; Kevin N. Sheth; Richa Sharma is a Medicine article available to read on EtoBox.
What is Left Ventricular Dysfunction Among Patients With Embolic Stroke of Undetermined Source and the Effect of Rivaroxaban vs Aspirin: A Subgroup Analysis of the NAVIGATE ESUS Randomized Clinical Trial about?
It is uncertain whether anticoagulation is superior to aspirin at reducing recurrent stroke in patients with recent embolic strokes of undetermined source (ESUS) and left ventricular (LV) dysfunction. OBJECTIVE To determine whether anticoagulation is superior to aspirin in reducing recurrent stroke in patients with ESUS and LV dysfunction. DESIGN, SETTING, AND PARTICIPANTS Post hoc exploratory analysis of data from the New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial vs Aspirin to Prevent Embolism in ESUS (NAVIGATE ESUS) trial, a randomized, phase 3 clinical trial with enrollment from December 2014 to September 2017. The study setting included 459 stroke recruitment centers in 31 countries. Patients 50 years or older who had neuroimaging-confirmed ESUS between 7 days and 6 months before screening were eligible. Of the 7213 NAVIGATE ESUS participants, 7107 (98.5%) had a documented assessment of LV function at study entry and were included in the present analysis. Data were analyzed in January 2021. INTERVENTIONS Participants were randomized to receive either 15 mg of rivaroxaban or 100 mg of aspirin once daily. ## MAIN OUTCOMES AND MEASURES The study examined wheth
Who reads Left Ventricular Dysfunction Among Patients With Embolic Stroke of Undetermined Source and the Effect of Rivaroxaban vs Aspirin: A Subgroup Analysis of the NAVIGATE ESUS Randomized Clinical Trial?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Alexander E. Merkler; Lesly A. Pearce; Scott E. Kasner; Ashkan Shoamanesh; Lee A. Birnbaum; Hooman Kamel; Kevin N. Sheth; Richa Sharma
- Published
- 2021
- Language
- EN
- Field
- Medicine (Health Sciences)